PTHS (Pelthos Therapeutics) Short Interest


PTHS Pelthos Therapeutics Inc PTHS
8 GF Score
Price $29.03
! 5 Warning Signs
View Full Analysis

What is Pelthos Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

PTHS vs CGTX, BDTX, CBUS: Short Interest Comparison

For the Biotechnology subindustry, Pelthos Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pelthos Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pelthos Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Pelthos Therapeutics's Short Interest falls into.


PTHS
8GF Score
Pelthos Therapeutics Inc PTHS
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pelthos Therapeutics Business Description

Address 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score

Get the complete analysis for PTHS

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.03
Price